Reduced Cholecystokinin Immunoreactivity in the Cerebrospinal Fluid of Patients with Psychiatric Disorders
Overview
Biology
Physiology
Affiliations
The close relationship of cholecystokinin peptides with some of the dopamine pathways and the limbic system suggests a putative role for these peptides in the pathophysiology of neuropsychiatric disorders such as Parkinson's disease, manic-depression and schizophrenia. By use of radioimmunoassay, we report a significant decrease in cholecystokinin-immunoreactivity in the cerebrospinal fluid of patients with bipolar manic-depression and untreated schizophrenia in comparison to control subjects.
Romer T, Jeppesen R, Christensen R, Benros M Mol Psychiatry. 2023; 28(6):2277-2290.
PMID: 37169812 DOI: 10.1038/s41380-023-02059-2.
Ballaz S, Bourin M, Akil H, Watson S Prog Neuropsychopharmacol Biol Psychiatry. 2019; 96:109761.
PMID: 31526831 PMC: 6935156. DOI: 10.1016/j.pnpbp.2019.109761.
Shlik J, Vasar E, Bradwejn J CNS Drugs. 2013; 8(2):134-52.
PMID: 23338219 DOI: 10.2165/00023210-199708020-00005.
van Dijk K, Teunissen C, Drukarch B, Jimenez C, Groenewegen H, Berendse H Neurobiol Dis. 2010; 39(3):229-41.
PMID: 20451609 PMC: 7126274. DOI: 10.1016/j.nbd.2010.04.020.
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
De Wied D, Sigling H Neurotox Res. 2003; 4(5-6):453-468.
PMID: 12754159 DOI: 10.1080/10298420290031432.